In This Article:
As global markets continue to react to political developments and economic indicators, major indexes like the S&P 500 have reached new highs amid optimism over potential trade deals and AI investments. In this environment of fluctuating growth and value stock performance, identifying stocks that are estimated to be below their intrinsic value can offer opportunities for investors seeking long-term gains.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Sichuan Injet Electric (SZSE:300820) | CN¥50.58 | CN¥100.77 | 49.8% |
| GlobalData (AIM:DATA) | £1.78 | £3.56 | 49.9% |
| Fudo Tetra (TSE:1813) | ¥2192.00 | ¥4357.83 | 49.7% |
| J Trust (TSE:8508) | ¥520.00 | ¥1039.92 | 50% |
| Bufab (OM:BUFAB) | SEK464.20 | SEK926.28 | 49.9% |
| Greenworks (Jiangsu) (SZSE:301260) | CN¥13.83 | CN¥27.64 | 50% |
| IDP Education (ASX:IEL) | A$13.17 | A$26.31 | 49.9% |
| Allied Blenders and Distillers (NSEI:ABDL) | ₹394.40 | ₹787.12 | 49.9% |
| Condor Energies (TSX:CDR) | CA$1.83 | CA$3.64 | 49.7% |
| Vista Group International (NZSE:VGL) | NZ$3.24 | NZ$6.15 | 47.3% |
Below we spotlight a couple of our favorites from our exclusive screener.
Harvia Oyj
Overview: Harvia Oyj is a company that manufactures and distributes traditional, steam, and infrared saunas, with a market cap of €885.39 million.
Operations: The company's revenue segment includes Building Materials - HVAC Equipment, generating €163.66 million.
Estimated Discount To Fair Value: 10.1%
Harvia Oyj's recent earnings report shows a positive trend, with net income for the third quarter increasing to €5.46 million from €4.47 million year-over-year, and nine-month sales reaching €124.25 million. Despite a high debt level, Harvia is trading 10.1% below its estimated fair value of €52.26 per share, suggesting it could be undervalued based on discounted cash flow analysis. Projected earnings growth outpaces the Finnish market at 17.3% annually.
-
The analysis detailed in our Harvia Oyj growth report hints at robust future financial performance.
-
Get an in-depth perspective on Harvia Oyj's balance sheet by reading our health report here.
SK Biopharmaceuticals
Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on the research and development of drugs for central nervous system disorders, with a market cap of approximately ₩8.55 trillion.
Operations: The company generates revenue from its New Drug Development segment, totaling approximately ₩511.33 million.
Estimated Discount To Fair Value: 45.1%
SK Biopharmaceuticals is trading significantly below its estimated fair value of ₩198,795.73 at ₩109,200, indicating potential undervaluation based on cash flows. The company's earnings and revenue are forecast to grow substantially faster than the Korean market, with earnings expected to increase by over 51% annually. Recent strategic alliances in radiopharmaceutical research may enhance its pipeline and contribute to this growth trajectory, despite high non-cash earnings levels.